Feedback

EU regulator recommends Merck’s Covid-19 pill for emergency use

Source : 112 Ukraine

Molnupiravir, which is produced by Merck and Ridgeback Biotherapeutics, can be given within five days of first symptoms to treat adults who do not need oxygen support and are at risk of severe disease
09:23, 20 November 2021

Merck

The European Medicines Agency (EMA) has advised its member states they can use a potentially groundbreaking Covid-19 antiviral pill in emergency situations. This was reported by the press service of the EMA

Molnupiravir, which is produced by Merck and Ridgeback Biotherapeutics, can be given within five days of first symptoms to treat adults who do not need oxygen support and are at risk of severe disease.

Related: Ukraine begins testing Pfizer, Merck pills from Covid

The EMA said it had issued its advice to support national authorities who may be keen to deploy the pill, to be branded Lagevrio in Europe, ahead of it gaining full authoristation from the regulator “in light of rising rates of infection and deaths due to Covid-19 across the EU”.

The EMA’s decision came after former EU member state the United Kingdom became the first country in the world to greenlight molnupiravir for use earlier in November.

As we reported earlier, the EU approved two drugs, Ronaprev (casirivimab/imdevimab) and Regkiron (regdanvimab) for the treatment of coronavirus. 

"Treatment with Ronaprev or Regquiron significantly reduces hospitalizations and deaths in patients with Covid-19 at risk for severe Covid-19. Another study showed that Ronaprev reduces the likelihood of contracting Covid-19 if a family member is infected with SARS-CoV-2, the virus that causes Covid-19," the committee concluded.

Related: Law on emergency use of coronavirus pills comes into force in Ukraine

Topics:
Система Orphus

If you find an error, highlight the desired text and press Ctrl + Enter, to tell about it

Comments
see more